Hypercalcemia

Hypercalcemia is defined as a total serum calcium concentration exceeding the upper limit of normal, typically >10.5 mg/dL (2.6 mmol/L) after correction for albumin, or an ionized calcium level >1.32 mmol/L. It is a common electrolyte disorder encountered across inpatient and outpatient settings, with primary hyperparathyroidism (PHPT) and malignancy accounting for more than 90% of cases ^[3]A1c.

Also Called / Synonyms

• Hypercalcemia (standard term)
• Hypercalcaemia (British spelling)
• Calcium intoxication (historical, now reserved for severe cases)
• Hypercalcemic crisis (severe, symptomatic hypercalcemia)
• Paraneoplastic hypercalcemia (when due to malignancy)

Severity Staging

Severity is stratified by total calcium level and guides urgency of intervention:

• Mild: 10.5-11.9 mg/dL (2.6-2.97 mmol/L)
• Moderate: 12.0-13.9 mg/dL (3.0-3.47 mmol/L)
• Severe: ≥14.0 mg/dL (3.5 mmol/L), often termed hypercalcemic crisis Ionized calcium thresholds are less standardized but generally >1.45 mmol/L is considered severe.

Classification by Etiology

Hypercalcemia is classified by the underlying mechanism into PTH-dependent and PTH-independent categories. The following table summarizes the major types:

Axis Nomenclature

The term "primary hyperparathyroidism" denotes autonomous parathyroid hormone (PTH) secretion leading to hypercalcemia. Secondary hyperparathyroidism is a compensatory rise in PTH due to hypocalcemia (e.g., chronic kidney disease, vitamin D deficiency) and is not associated with hypercalcemia. Tertiary hyperparathyroidism occurs when prolonged secondary hyperparathyroidism leads to autonomous parathyroid function, typically after renal transplantation, and can cause hypercalcemia. In the context of hypercalcemia, the axis is best described as PTH-dependent (elevated or inappropriately normal PTH) versus PTH-independent (suppressed PTH) ^[3]A1c.

Clinical Significance

Hypercalcemia is a potentially life-threatening metabolic emergency. In hospitalized patients, malignancy-associated hypercalcemia carries a poor prognosis, with median survival often measured in weeks to months ^[2]B2b. PHPT, while usually milder, is associated with increased risk of nephrolithiasis, osteoporosis, and cardiovascular events ^[8]B3b. Early recognition and classification by axis are essential for appropriate management .

Controversies and Guideline Disagreement

There is ongoing debate regarding the diagnostic criteria for normocalcemic PHPT, where PTH is elevated but total and ionized calcium are normal. The Endocrine Society and European Society of Endocrinology differ slightly in recommended thresholds for diagnosis and indications for surgery ^[1]D5[3]A1c. Additionally, the distinction between FHH and mild PHPT can be challenging; a 24-hour urinary calcium-to-creatinine clearance ratio <0.01 favors FHH, but genetic testing is definitive ^[3]A1c.

Pearl: Hypercalcemia is not a diagnosis but a biochemical clue; the PTH level is the single most important test to narrow the differential, with a suppressed PTH pointing to malignancy or other non-parathyroid causes ^[3]A1c.

The Calcium-PTH-Vitamin D Axis in Normal Physiology

Calcium homeostasis depends on a three-organ feedback loop whose set point is extraordinarily precise: total serum calcium is maintained within 2.2-2.6 mmol/L (8.5-10.5 mg/dL) across a wide range of dietary intake ^{[11]A1b[22]D5}. The calcium-sensing receptor (CaSR), a G-protein-coupled receptor expressed chiefly on parathyroid chief cells, is the system's primary sensor. A 0.1-mmol/L fall in ionized calcium reduces CaSR activation, triggering a rapid increase in parathyroid hormone (PTH) secretion within seconds to minutes. Basal PTH secretion is effectively constant, but CaSR signaling tonically suppresses it; loss of CaSR activation disinhibits PTH release ^[15]C4[22]D5.

PTH then acts on three targets: (1) bone - it binds PTH receptor 1 (PTH1R) on osteoblasts, which in turn stimulate osteoclast-mediated bone resorption, releasing calcium and phosphate into the circulation; (2) kidney - it increases distal tubular calcium reabsorption and proximal tubular phosphate excretion, and stimulates renal 1α-hydroxylase (CYP27B1) to convert 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (calcitriol); and (3) intestine - calcitriol binds the vitamin D receptor (VDR) to upregulate active intestinal calcium absorption ^[20]D5[29]D5.

Breakpoints: Where the Axis Fails

Every cause of hypercalcemia arises from an abnormality at one or more of three nodes: excessive bone resorption, increased intestinal calcium absorption, or decreased renal calcium excretion ^[19]D5[29]D5. The biochemical patterns that fingerprint each cause depend on which node is primarily deranged and whether PTH is the mediator or a bystander.

1. Parathyroid-Mediated (Elevated PTH, Normal or Elevated Calcitriol)

Primary hyperparathyroidism (PHPT) is driven by a parathyroid adenoma (≈85%), hyperplasia (≈15%), or carcinoma (<1%) that loses normal CaSR suppression ^{[11]A1b[26]C4}. A somatic or germline mutation in the MEN1, RET, or CDC73 (parafibromin) genes, or loss of CaSR itself, resets the set point for PTH secretion upward. The result is PTH-dependent hypercalcemia: serum calcium is elevated, PTH is either frankly elevated or inappropriately in the upper-normal range for the calcium level, 1,25-dihydroxyvitamin D is normal or elevated (because PTH drives CYP27B1), and phosphate is low due to PTH-mediated phosphaturia ^{[12]B2a[26]C4}. This is the classic signature.

Parathyroid carcinoma retains the same biochemical signature but is distinguished by very high PTH levels, severe hypercalcemia (often >3.5 mmol/L), and palpable neck mass. Loss of parafibromin expression (encoded by CDC73) is seen in 40-60% of carcinomas and correlates with worse prognosis ^[14]C4[26]C4.

2. Humoral Hypercalcemia of Malignancy (HHM): Suppressed PTH, Elevated PTHrP, Low Calcitriol

Ectopic PTHrP secretion by solid tumors, most commonly squamous cell carcinomas of lung, head and neck, esophagus, cervix, and breast, accounts for ≈80% of malignancy-associated hypercalcemia ^{[21]D5[28]A1a[35]B3a}. PTHrP binds the same PTH1R as PTH, but with distinct tissue effects: it stimulates bone resorption and distal tubular calcium reabsorption as PTH does, but it does not stimulate renal 1α-hydroxylase. Consequently, 1,25-dihydroxyvitamin D is low (or low-normal), and PTH is suppressed by hypercalcemia ^[21]D5[37]D5.

The biochemical signature is thus: hypercalcemia + suppressed PTH + elevated PTHrP + low calcitriol + normal or low phosphate. In breast cancer, PTHrP expression also correlates with bone metastasis risk and poorer outcomes (HR 1.42, 95% CI 1.20-1.69; NNT not calculable) ^[28]A1a.

3. Calcitriol-Mediated: Suppressed PTH, Suppressed PTHrP, Elevated 1,25(OH)2D

In granulomatous diseases (sarcoidosis, tuberculosis, leprosy, fungal infections) and some lymphomas (Hodgkin and non-Hodgkin), activated macrophages or lymphoma cells express CYP27B1 and convert 25-hydroxyvitamin D to calcitriol in an unregulated, PTH-independent manner ^[17]C4[29]D5. This increases intestinal calcium absorption and bone resorption. PTH is suppressed; PTHrP is undetectable; 1,25-dihydroxyvitamin D is elevated; 25-hydroxyvitamin D is normal. The same pattern occurs in some patients with langerhans cell histiocytosis or dermatopathic lymphadenopathy after COVID-19 infection, where granulomatous inflammation drives ectopic calcitriol production ^[32]C4.

4. Calcium-Sensing Receptor Disorders: Genetic and Autoimmune

Loss-of-function mutations in the CASR gene cause familial hypocalciuric hypercalcemia (FHH) type 1, an autosomal dominant condition in which the parathyroid gland perceives an inappropriately low calcium signal. PTH is normal or mildly elevated, but the hallmark is a low fractional excretion of calcium (FECa <1%) because the kidney also carries the mutant CaSR and fails to excrete calcium appropriately ^{[13]B2a[22]D5[25]D5}. FHH type 2 (GNA11 mutation) and type 3 (AP2S1 mutation) produce an identical biochemical pattern by disrupting CaSR signaling at the G-protein or endocytic adaptor level ^[27]B3b.

Autoantibodies against the CaSR can produce an acquired counterpart: acquired hypocalciuric hypercalcemia with lymphocytic parathyroiditis. Here, anti-CaSR antibodies block receptor activation, causing PTH-dependent hypercalcemia that mimics FHH but is glucocorticoid-responsive ^[17]C4.

5. Vitamin D Intoxication and Exogenous Sources

Excessive vitamin D supplementation (typically >40,000 IU/day for weeks to months) leads to massive accumulation of 25-hydroxyvitamin D (>150 ng/mL). 25(OH)D competes for binding at the VDR, albeit with lower affinity than calcitriol, but at supraphysiologic concentrations it activates the receptor directly, driving intestinal hyperabsorption and bone resorption. The signature is elevated 25(OH)D, suppressed PTH, and low-normal 1,25(OH)2D ^[29]D5.

6. Ectopic PTH Secretion (Rare)

True ectopic PTH secretion is exceedingly rare but well-documented from paraneoplastic syndromes of adrenocortical carcinoma , small-cell lung cancer, ovarian tumors, and others. Both PTH mRNA expression and immunoreactive PTH in tumor tissue have been confirmed; the biochemical pattern is identical to PHPT (elevated PTH, normal PTHrP, normal calcitriol) ^[16]C4[37]D5.

The Integrated Pathophysiologic Cascade

Step by step, the final pathway to hypercalcemia can be summarized as a numbered chain:

1. Sensor fails or is bypassed - CaSR is inactivated by mutation ^[13]B2a, antibody ^[17]C4, or tumor-gene loss ^[26]C4; or PTH/PTHrP/calcitriol is produced from an ectopic or unregulated source ^[21]D5[29]D5.
2. Effector hormone is elevated inappropriately - PTH, PTHrP, or calcitriol acts on bone, kidney, and intestine.
3. Increased bone resorption - PTH1R on osteoblasts upregulates RANKL, which stimulates osteoclast maturation; denosumab blocks this by neutralizing RANKL ^{[30]A1a[33]C4}. Bisphosphonates inhibit farnesyl pyrophosphate synthase in osteoclasts ^[30]A1a.
4. Increased distal tubular calcium reabsorption - PTH and PTHrP increase Ca²⁺ reabsorption in the thick ascending limb and distal convoluted tubule via TRPV5 and claudin-14 upregulation ^{[11]A1b[21]D5}.
5. Increased intestinal calcium absorption - Calcitriol upregulates TRPV6 and calbindin-D₉K in enterocytes ^[20]D5[29]D5.
6. Renal calcium excretory capacity is overwhelmed - The combination of increased filtered load and enhanced reabsorption overcomes the kidney's ability to clear calcium, establishing a positive balance.
7. Systemic hypercalcemia triggers clinical manifestations - See Clinical Presentation section.

Tissue-Level Susceptibility Modifiers

• Age: Youths with PHPT often have higher PTH and calcium levels than adults, possibly reflecting differences in CaSR expression or gonadal hormone milieu ^[12]B2a.
• Renal function: Chronic kidney disease impairs calcium clearance and blunts calcitriol production, shifting the balance toward hypercalcemia from antiresorptive agents (denosumab, bisphosphonates) that accumulate ^[33]C4.
• Genetic background: Germline CASR hypomorphic variants are overrepresented in apparently sporadic PHPT, suggesting an oligogenic threshold effect ^{[13]B2a[25]D5}.

Table 1: Biochemical Signatures of the Major Hypercalcemia Subtypes

Pearl: The three-step diagnostic algorithm, measure PTH, then PTHrP if PTH is suppressed, then 1,25(OH)₂D if PTHrP is normal, rapidly classifies >95% of hypercalcemia cases. A low fractional excretion of calcium (<1%) should trigger evaluation for FHH, especially if PTH is not fully suppressed ^{[13]B2a[17]C4[27]B3b}.

Primary hyperparathyroidism (PHPT) and malignancy together account for 90% of hypercalcemia cases in ambulatory and hospitalized populations ^[19]D5[44]C4. The remaining 10% arise from rare genetic, granulomatous, endocrine, and iatrogenic causes. Understanding the relative frequencies, demographic patterns, and risk factors for each etiology directly shapes the diagnostic workup and urgency of intervention.

Incidence and Prevalence

PHPT affects 1 to 7 per 1,000 adults (prevalence ~0.1-0.7%) ^[44]C4. Incidence peaks in the fifth to sixth decade, with a marked female preponderance (female-to-male ratio ~3:1) ^[44]C4. The female predominance is less pronounced in younger age groups and may relate to estrogen-dependent effects on parathyroid cell proliferation and calcium-sensing set point.

Hypercalcemia of malignancy (HCM) is the most common metabolic complication of cancer, though its incidence is declining due to more potent chemotherapeutic agents ^[38]A1c. Among hospitalized patients, malignancy surpasses PHPT as the leading cause of hypercalcemia. The highest rates occur in advanced-stage solid tumors (lung, breast, renal cell, head and neck, esophageal) and hematologic malignancies ( multiple myeloma , lymphoma, adult T-cell leukemia/lymphoma) ^{[38]A1c[39]A1a}.

Temporal trends: The incidence of symptomatic HCM has decreased over the past two decades, likely due to earlier cancer diagnosis and widespread use of bone-modifying agents in metastatic disease ^[38]A1c. Conversely, the detection of mild, asymptomatic PHPT has risen with routine biochemical screening ^[44]C4.

Etiologic Classification

The three pathophysiologic mechanisms of hypercalcemia, increased bone resorption, increased intestinal absorption, and decreased renal calcium excretion, map to distinct disease categories:

Risk Factors

Several modifiable and non-modifiable risk factors increase the probability of hypercalcemia:

Non-modifiable:

• Female sex - PHPT risk is 3-fold higher in women, particularly postmenopausal ^[44]C4
• Age - PHPT incidence increases after age 50; HCM correlates with advancing cancer stage ^[39]A1a
• Family history - MEN1, MEN2A, MEN4, familial hypocalciuric hypercalcemia, and CYP24A1 mutations confer inherited risk ^{[43]B2b[51]C4}
• Race/ethnicity - PHPT is more common in White populations; sarcoidosis-associated hypercalcemia is more frequent in Black individuals

Modifiable:

• Lithium therapy - Chronic lithium use (≥10 years in bipolar disorder) increases risk of lithium-associated hyperparathyroidism (LAH), often with multiglandular disease ^[45]C4
• Thiazide diuretics - Reduce urinary calcium excretion; may unmask mild PHPT or precipitate hypercalcemia in patients with high bone turnover
• Vitamin D supplementation - Toxicity is rare but occurs with total intake exceeding 240,000 to 4,500,000 IU in children ^[49]D5; in adults, doses >10,000 IU/day chronically can cause hypercalcemia
• Vitamin A (retinoid) excess - Both acute (overdose) and chronic (supplements, acne therapy) exposure can cause hypercalcemia ^[53]C4
• Calcium-based phosphate binders - In dialysis patients, combined with active vitamin D analogs, can lead to hypercalcemia ^{[48]B2b[60]B2b}
• Denosumab rebound - After discontinuation, particularly in children, severe rebound hypercalcemia and metaphyseal band fractures can occur ^[24]B3b
• Immobilization - Prolonged bed rest increases osteoclastic bone resorption, especially in patients with high bone turnover (e.g., Paget disease, adolescents)

Risk Factor Summary Table

Seasonal Variation

Serum calcium exhibits mild seasonal variation, with highest levels in summer months due to increased cutaneous vitamin D synthesis. The effect is small (0.1-0.2 mg/dL) and rarely sufficient to cross diagnostic thresholds alone, but it can unmask borderline hypercalcemia in patients with underlying PHPT or granulomatous disease ^[19]D5. Seasonal screening artifacts must be considered when interpreting a single elevated calcium value in an otherwise asymptomatic patient.

Special Populations

Hospitalized patients: Hypercalcemia of malignancy predominates. In one systematic review supporting the Endocrine Society guideline, HCM occurred in 20-30% of patients with multiple myeloma and 8-10% of patients with lung or breast cancer during their disease course ^[39]A1a.

Dialysis patients: Hidden hypercalcemia (elevated ionized calcium with normal total calcium) is associated with increased mortality risk (HR for hidden hypercalcemia: ~1.3-1.5 vs. normocalcemic counterparts) ^[48]B2b. Both apparent and hidden hypercalcemia carry prognostic significance, underscoring the value of ionized calcium measurement in end-stage renal disease.

Neonates and infants: Subcutaneous fat necrosis (SCFN) of the newborn is a rare but important cause of hypercalcemia, typically appearing 1-6 weeks after birth. Risk factors include perinatal hypoxia, therapeutic hypothermia, and meconium aspiration ^[59]C4. Hypercalcemia in SCFN can be severe and require aggressive management .

Pearl: Two etiologies account for 90% of hypercalcemia, primary hyperparathyroidism in outpatients and malignancy in inpatients, making the clinical context the most powerful initial predictor of the underlying cause ^{[19]D5[38]A1c[44]C4}; always consider lithium, thiazides, vitamin D/ A excess, and granulomatous disease in the remaining 10%.

The clinical presentation of hypercalcemia spans a spectrum from an entirely asymptomatic laboratory finding to a life-threatening endocrine emergency ^[68]D5. The tempo of symptom onset often reflects the underlying cause: chronic, indolent hypercalcemia typifies primary hyperparathyroidism (PHPT), whereas acute, rapidly progressive hypercalcemia signals malignancy or granulomatous disease ^[29]D5[68]D5. Recognizing the syndrome at the bedside, before laboratory confirmation, requires a systematic approach to symptoms, neurologic examination, and variant-specific features.

Presenting Symptoms

Most patients with PHPT are asymptomatic, identified incidentally on routine biochemistry ^[68]D5. When symptoms occur, they follow the classic mnemonic "bones, stones, groans, psychic moans," but fatigue, cognitive slowing, and depression are more prevalent than frank psychosis ^[68]D5. Skeletal manifestations include bone pain, fragility fractures, and, in severe cases, brown tumors or skeletal deformities such as coxa vara and genu valgum, particularly in children and adolescents ^[76]C4. Nephrolithiasis occurs in 15-20% of PHPT patients, often recurrent, and nephrocalcinosis may be detected on imaging ^[68]D5. Gastrointestinal symptoms, constipation, nausea, vomiting, abdominal pain, are common with serum calcium >12 mg/dL (3.0 mmol/L). Polyuria and polydipsia result from hypercalcemia-induced nephrogenic diabetes insipidus.

In malignancy-associated hypercalcemia (MAH), symptoms evolve over days to weeks. Weight loss, anorexia, and bone pain dominate, and the hypercalcemia is often severe (>14 mg/dL [3.5 mmol/L]) ^[29]D5. Parathyroid carcinoma presents with extreme hypercalcemia (often >15 mg/dL), a palpable neck mass, and hoarseness from recurrent laryngeal nerve invasion ^[72]C4[73]C4. Acute urinary retention is a rare but reported presenting symptom ^[73]C4.

Infants with hypercalcemia exhibit nonspecific signs: poor feeding, irritability, constipation, and sterile pyuria, a critical clue that should prompt calcium measurement ^[75]C4. Children on a ketogenic diet may develop hypercalcemia without other obvious cause ^[65]C4. Patients with granulomatous disorders (e.g., sarcoidosis) often have pulmonary or cutaneous findings alongside hypercalcemia ^[71]B2b.

Neurological Examination Findings

Neurologic involvement correlates with both the severity and the rapidity of calcium elevation. Mild hypercalcemia (10.5-12 mg/dL) may cause only subjective fatigue or mild cognitive slowing. At moderate levels (12-14 mg/dL), objective findings emerge:

• Proximal muscle weakness: Difficulty rising from a chair or stepping onto a stool; hip flexor and shoulder abductor strength is diminished.
• Hyporeflexia: Deep tendon reflexes are reduced or absent.
• Mental status changes: Lethargy, confusion, disorientation, and impaired attention.
• Psychiatric disturbances: Depression, anxiety, and, rarely, psychosis with hallucinations.

Severe hypercalcemia (>14 mg/dL) can progress to stupor, coma, and seizures. Cranial nerve function is typically spared unless the hypercalcemia is extreme. Autonomic instability is uncommon but may manifest as orthostatic hypotension due to volume depletion.

Examination maneuvers: Assess proximal strength by asking the patient to perform a deep knee bend or rise from a seated position without using arms. Test hip flexors against resistance. Evaluate mental status with the Mini-Mental State Examination or a simple attention task (e.g., serial sevens).

Phenotypic Variants

The following table summarizes the distinguishing clinical features of common hypercalcemia variants:

Red Flags

Certain presentations demand immediate action:

• Serum calcium >14 mg/dL (3.5 mmol/L), hypercalcemic crisis with risk of coma, cardiac arrest, and acute kidney injury.
• Altered mental status, stupor or coma requires urgent intravenous fluids and calcitonin/bisphosphonate therapy.
• Acute kidney injury, often prerenal from volume depletion; may progress to acute tubular necrosis .
• Pathological fracture, especially in young patients, suggests parathyroid carcinoma or severe PHPT ^[72]C4.
• Acute urinary retention, rare but reported in parathyroid carcinoma ^[73]C4.
• Short QT interval on ECG, predisposes to ventricular arrhythmias ; monitor cardiac rhythm.

Atypical Presentations

Hypercalcemia may be missed when it presents in unusual ways:

• Sterile pyuria in infants, a key clue to hypercalcemia-induced nephrocalcinosis ^[75]C4.
• Skeletal deformities in children, coxa vara and genu valgum can be the first sign of PHPT ^[76]C4.
• Acute urinary retention, consider hypercalcemia in middle-aged men without prostatic enlargement ^[73]C4.
• Cosmetic injection-associated hypercalcemia, granulomatous reaction to silicone or polymethylmethacrylate injections presents with fever, arthralgias, and hypercalcemia months to years after procedure ^[61]C4.
• Ketotic hypercalcemia, children on ketogenic diet may develop hypercalcemia without other etiology ^[65]C4.
• Masked hypercalcemia, in patients with hypoparathyroidism on calcium/vitamin D supplements, hypercalcemia may be attributed to overtreatment but actually reflect an intercurrent granulomatous or malignant process ^[64]C4.

Pearl: The clinical spectrum of hypercalcemia ranges from incidental laboratory finding to life-threatening emergency; a high index of suspicion for atypical presentations, sterile pyuria in infants, acute urinary retention in adults, or skeletal deformities in children, can expedite diagnosis and prevent irreversible organ damage ^{[68]D5[75]C4[76]C4}.

Biochemical confirmation of the cause must precede any localization study. Ordering a neck ultrasound before the parathyroid hormone (PTH) concentration is known wastes resources and risks misdirection, a positive sestamibi scan in a patient with familial hypocalciuric hypercalcemia (FHH) can lead to unnecessary neck exploration ^[3]A1c[86]D5. The diagnostic engine runs on two sequential phases: first, a paired static biochemical profile plus, when indicated, a dynamic suppression test; second, dedicated anatomic imaging with venous sampling reserved for discordant or reoperative cases.

Step 1, The Paired Biochemical Profile

A single morning blood draw must include albumin-corrected total calcium, intact PTH, phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and creatinine. A simultaneously collected 24-hour urine measures calcium, creatinine, and sodium. The corrected calcium is calculated as: measured total calcium (mg/dL) + 0.8 × (4.0 - albumin [g/dL]). Ionized calcium can substitute when albumin abnormalities are extreme, but corrected calcium suffices in routine practice ^[29]D5[68]D5.

Interpretation hinges on the PTH-calcium relationship. A frankly elevated PTH (>65 pg/mL) with hypercalcemia points to PTH-dependent disease, primarily primary hyperparathyroidism (PHPT), but also tertiary hyperparathyroidism in chronic kidney disease, lithium therapy, or FHH with a co-incident parathyroid adenoma ^[3]A1c[86]D5. A suppressed PTH (<20 pg/mL) in the face of hypercalcemia defines PTH-independent hypercalcemia, a category dominated by malignancy, granulomatous disease, vitamin D intoxication, and the rare CYP24A1 deficiency ^{[29]D5[80]C4[81]C4}.

A low-normal or frankly low PTH (20-40 pg/mL) with hypercalcemia in a patient who otherwise fits PHPT still warrants a workup for FHH; in this gray zone, the calcium-to-creatinine clearance ratio (CCCR) separates the two entities. A CCCR <0.01 strongly suggests FHH, while a value >0.02 is typical of PHPT ^{[3]A1c[86]D5[90]B3b}. The ratio is calculated as: (urine calcium × serum creatinine) / (serum calcium × urine creatinine). Among 11 genetically confirmed FHH1 patients in a Chinese cohort, the mean CCCR was 0.006 ± 0.003 versus 0.026 ± 0.015 in sporadic PHPT (P < 0.001) ^[90]B3b.

Table 1. Biochemical Discriminators Between Primary Hyperparathyroidism and Familial Hypocalciuric Hypercalcemia

Adapted from ^{[3]A1c[86]D5[90]B3b}

Step 2, Dynamic Suppression Testing

When the PTH is mildly elevated and the CCCR is borderline (0.01-0.02), the oral calcium suppression test can resolve diagnostic ambiguity. The patient ingests 1 g of elemental calcium (e.g., four 250-mg calcium carbonate tablets) orally, and serum calcium and PTH are measured at baseline, 1 hour, and 2 hours. In FHH, the calcium-sensing receptor (CaSR) is resistant; PTH does not suppress by more than 20% from baseline, and the peak serum calcium increases by <1.2 mg/dL. In PHPT, PTH suppresses by >50% (though often not to normal), and the calcium rise exceeds 1.2 mg/dL ^[3]A1c[46]C4. This test is safe in mild hypercalcemia but contraindicated if the baseline calcium exceeds 12 mg/dL ^[3]A1c.

Genetic testing for CASR, AP2S1, and GNA11 mutations should be offered when FHH is suspected, especially before proceeding to parathyroid imaging or surgery ^{[89]B3b[90]B3b}. One cohort of 82 families found presumed inactivating CASR mutations in 26 families (32%), all had hypercalcemia with median PTH of 52 pg/mL and a CCCR <0.01 ^[89]B3b.

Step 3, Localization Studies

Once the biochemical diagnosis confirms PHPT, localization imaging is mandatory before any surgical intervention. The first-line imaging study is high-resolution neck ultrasound (US) performed by an experienced sonographer. Its sensitivity for a solitary adenoma ranges from 70% to 85%, with a positive predictive value of 90% when a discrete lesion is seen ^{[3]A1c[78]A1a}. Second-line imaging is 99mTc-sestamibi single-photon emission computed tomography (SPECT/CT). Sestamibi SPECT/CT has a sensitivity of 80-90% and provides excellent anatomic correlation, particularly for ectopic adenomas in the mediastinum or carotid sheath ^[3]A1c[82]C4. When US and sestamibi are discordant or negative, four-dimensional computed tomography (4D-CT), which captures the perfusion kinetics of parathyroid adenomas, achieves a sensitivity approaching 90% for single-gland disease ^[3]A1c.

Table 2. Localization Imaging Modalities for Primary Hyperparathyroidism

Adapted from ^{[3]A1c[78]A1a[82]C4}

For patients with suspected parathyroid carcinoma , the imaging picture is distinct: a large (>3 cm), irregular, hypoechoic mass with internal echoes and possibly cystic degeneration on US, with intense and early uptake on sestamibi and 4D-CT. Invasion of adjacent structures (thyroid, carotid artery, recurrent laryngeal nerve) is suspicious. However, no imaging finding reliably distinguishes carcinoma from benign adenoma preoperatively ^[84]D5[85]D5.

Step 4, Invasive Venous Sampling

Selective parathyroid venous sampling (SVS) is reserved for reoperative cases (persistent or recurrent PHPT after previous neck surgery) or when noninvasive imaging yields negative or equivocal results. Under fluoroscopic guidance, the interventional radiologist samples veins draining the four parathyroid beds, the bilateral superior, middle, and inferior thyroid veins, plus peripheral veins. A PTH gradient of ≥2-fold above peripheral levels localizes the hypersecreting gland. SVS has a sensitivity of 80-90% in reoperative PHPT ^[3]A1c[84]D5.

The role of SVS in MEN1: Patients with multiple endocrine neoplasia type 1 (MEN1) typically have multiglandular hyperplasia, not solitary adenoma. In this population, preoperative imaging is performed to identify the dominant glands but SVS is rarely needed because subtotal parathyroidectomy (removal of 3.5 glands) is standard ^[85]D5[88]D5.

Step 5, When to Suspect PTH-Independent Hypercalcemia

If PTH is suppressed, the diagnostic pathway pivots. The first branching question: is the hypercalcemia driven by 1,25-dihydroxyvitamin D or by PTH-related peptide (PTHrP)?

• Elevated 1,25-dihydroxyvitamin D with suppressed 25-hydroxyvitamin D: think granulomatous disease (sarcoidosis, tuberculosis, Blau syndrome), lymphoma, or CYP24A1 deficiency. The mechanism is extrarenal 1α-hydroxylase activity ^{[29]D5[80]C4[91]C4}. Measurement of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D is essential; a 25(OH)D <30 ng/mL rules out simple vitamin D intoxication, while 1,25-dihydroxyvitamin D >60 pg/mL points to a calcitriol-mediated state ^[29]D5.
• Elevated PTHrP: almost always due to malignancy (squamous cell lung cancer, breast cancer, renal cell carcinoma , ovarian cancer, adult T-cell leukemia/lymphoma). PTHrP should be measured in any hypercalcemic patient with a suppressed PTH and a known or suspected cancer ^[3]A1c[92]C4.
• Elevated 25-hydroxyvitamin D (>150 ng/mL): indicates vitamin D intoxication from excessive supplementation. Hypervitaminosis D also elevates 1,25-dihydroxyvitamin D but not to the same degree as granulomatous disease ^[29]D5[53]C4.
• Low PTH and low PTHrP with normal vitamin D metabolites: consider multiple myeloma (which causes hypercalcemia via osteoclast activation through RANKL, not PTHrP) or Addison disease (adrenal insufficiency, hypercalcemia resolves with glucocorticoid replacement) ^[92]C4[93]C4.

Step 6, Biopsy and Histology

Parathyroid carcinoma: a biopsy is not required before surgery, the diagnosis is made only after en-bloc resection and histopathologic examination showing invasive growth (capsular invasion, vascular invasion, perineural invasion) or metastases. A preoperative fine-needle aspiration should never be performed for a suspected parathyroid lesion; it risks tumor seeding and tract recurrence ^[84]D5[85]D5. When a specimen is sent, the pathologist should report tumor size, the presence of a fibrous capsule, the Ki-67 proliferation index (typically >5% in carcinoma vs <5% in adenoma), and evidence of vascular invasion. A definitive diagnosis of carcinoma requires invasion of surrounding structures or documented metastasis ^{[84]D5[85]D5[72]C4}.

Granulomatous disease: when sarcoidosis or tuberculosis is suspected, tissue biopsy of accessible lymph nodes, lung, or skin, with culture and PCR for mycobacteria, is indicated. Non-caseating granulomas with Schaumann bodies are classic for sarcoidosis. The presence of NOD2 gene mutation confirms Blau syndrome ^[91]C4.

Diagnostic Algorithm

Step 1: Confirm hypercalcemia with repeat corrected calcium or ionized calcium.

Step 2: Measure intact PTH, calcium, phosphate, 25(OH)D, 1,25(OH)₂D, creatinine, and 24-h urine calcium.

Step 3: Assess PTH-calcium relationship:

• If PTH elevated → PHPT or FHH: calculate CCCR. If CCCR <0.01, consider oral calcium suppression test ± CASR sequencing. If CCCR >0.02, proceed to localization imaging.
• If PTH suppressed → PTH-independent hypercalcemia: measure PTHrP, 25(OH)D, 1,25(OH)₂D, serum protein electrophoresis, and consider workup for granulomatous disease.

Step 4: If PHPT is confirmed: order neck US and sestamibi SPECT/CT. If discordant or negative, obtain 4D-CT before referring for parathyroidectomy.

Step 5: If localization studies fail and the patient is a surgical candidate, refer for selective parathyroid venous sampling.

Step 6: For suspected parathyroid carcinoma (severe hypercalcemia, palpable mass, vocal cord palsy): proceed directly to en-bloc resection with the ipsilateral thyroid lobe without preoperative biopsy ^[84]D5[85]D5.

Pearl: The single most important step in the hypercalcemia workup is to appropriately distinguish PTH-dependent from PTH-independent hypercalcemia by suppressing the PTH less than 20 pg/mL; once that branch is correctly assigned, the subsequent imaging and therapeutic decisions follow a clear, evidence-based pathway ^{[3]A1c[29]D5[86]D5}.

Once the diagnosis of hypercalcemia is confirmed, the next essential step is to assign a severity grade and a risk tier that will directly dictate the urgency and intensity of intervention. Severity is defined by the albumin-corrected serum calcium level, recalculated using the standard formula: corrected Ca (mg/dL) = measured total Ca + 0.8 × (4.0 - serum albumin in g/dL). Thresholds used in the Endocrine Society Guideline and across most cancer registries stratify hypercalcemia into three categories: mild (10.5-11.9 mg/dL or 2.62-2.96 mmol/L), moderate (12.0-13.9 mg/dL or 2.97-3.46 mmol/L), and severe (≥14.0 mg/dL or ≥3.47 mmol/L) ^{[38]A1c[99]C4}. This classification is not merely descriptive, it defines the treatment pathway. Mild hypercalcemia often warrants observation or outpatient oral therapy; moderate disease typically requires intravenous fluids and consideration of bisphosphonates; severe hypercalcemia is a medical emergency mandating hospital admission, aggressive IV hydration, and prompt use of calcitonin, bisphosphonates, and often denosumab or dialysis ^{[38]A1c[39]A1a}.

Calcium Thresholds and Clinical Decision Points

Bold thresholds mark key decision points. A serum calcium of ≥14 mg/dL (3.47 mmol/L) is the classic 'crisis' cutoff, but the absolute number must be interpreted in the context of the rate of rise and the patient's symptom burden. A patient with chronic mild hypercalcemia (e.g., 11.2 mg/dL from primary hyperparathyroidism ) may be asymptomatic, while a rapid climb to 13 mg/dL over 48 hours in malignancy can precipitate obtundation and cardiac arrhythmia. The 2023 Endocrine Society guideline emphasizes that hypercalcemia of malignancy (HCM) is a high-mortality condition, the 30-day mortality for patients with HCM is approximately 30%, and the one-year mortality exceeds 80% for those with advanced solid tumors ^{[38]A1c[99]C4}. Therefore, the risk tier in malignancy is severe by default, regardless of the absolute calcium level, if the patient is symptomatic or has a rising trend.

Risk Stratification by Etiology

Beyond the calcium number, risk stratification requires identifying the underlying mechanism. The most dangerous hypercalcemias are those driven by PTHrP-mediated bone resorption in solid tumors (squamous cell lung, breast, renal, ovarian) and by local osteolytic destruction in multiple myeloma and breast cancer ^{[99]C4[28]A1a}. PTHrP-driven hypercalcemia is particularly treacherous because it is often refractory to standard hydration and bisphosphonates, and it correlates with poor survival. In one large series of 138 patients with PTHrP-mediated hypercalcemia, the median survival from diagnosis was only 4 months for malignant causes ^[99]C4. Multiple myeloma adds another layer of risk: hypercalcemia is present at diagnosis in 15-20% of patients and is associated with higher tumor burden, lytic bone lesions, and a greater risk of renal failure ^{[92]C4[104]B3b}. The International Myeloma Working Group includes hypercalcemia (defined as corrected Ca >11 mg/dL) as one of the CRAB criteria (hyperCalcemia, Renal insufficiency, Anemia, Bone lesions) that defines end-organ damage and indicates the need for immediate systemic therapy ^[104]B3b.

Primary hyperparathyroidism (PHPT) generally carries a much lower risk profile. In PHPT, the serum calcium is usually stable and mild to moderate (rarely exceeds 12.5 mg/dL), and the natural history over a decade shows only slow progression of renal impairment and bone loss ^[101]B2b. However, risk stratification in PHPT still matters: patients with a serum calcium >1 mg/dL above the upper limit of normal (i.e., >11.5 mg/dL), creatinine clearance <60 mL/min, or a T-score ≤ -2.5 at any site meet guideline criteria for parathyroidectomy , not because of immediate crisis but because of long-term complications ^{[95]B2b[101]B2b}. Cinacalcet is reserved for those who cannot undergo surgery or have failed prior parathyroidectomy ^[95]B2b.

Multifactorial and Iatrogenic Hypercalcemia

Hypercalcemia in hospitalized patients often has multiple contributing factors. Immobilization, especially in patients with spinal cord injury or prolonged bed rest, acutely increases bone resorption and can push a borderline calcium into the moderate-to-severe range ^[94]A1b. Thiazide diuretics and lithium use are additional iatrogenic risks that must be screened for at presentation ^[61]C4. In patients with granulomatous diseases (sarcoidosis, tuberculosis, silicone granulomas from cosmetic injections), the hypercalcemia is driven by unregulated 1,25-dihydroxyvitamin D production by macrophages, and the severity correlates with the granulomatous burden and vitamin D intake ^[61]C4. These patients often have normal or suppressed PTH and PTHrP, which distinguishes them on the diagnostic workup.

Stratification for Acute Pancreatitis and Renal Failure

Hypercalcemia itself can cause acute pancreatitis. In an international multicenter cohort, hypercalcemia-induced acute pancreatitis was associated with significantly higher rates of organ failure and renal failure compared to other etiologies ^[103]B2b. Among 16 patients with pure hypercalcemic etiology (calcium >2.6 mmol/L), severe pancreatitis occurred in 75% versus 26% in controls (OR 8.7, p <0.001). This means that any patient with acute pancreatitis and hypercalcemia >2.6 mmol/L should be treated as high risk for a complicated course, and aggressive calcium-lowering should be initiated simultaneously with pancreatitis management .

Putting It All Together: A Pragmatic Risk Tier

A practical bedside risk stratifier integrates three variables: corrected calcium level, etiology/mechanism, and symptom status. The Endocrine Society guideline ^[38]A1c and the systematic review ^[39]A1a provide a framework that can be summarized as:

This tiered approach ensures that the most aggressive therapy is reserved for patients with the highest risk of poor outcome, while avoiding unnecessary hospitalization and treatment for those with low-risk chronic hypercalcemia.

Pearl: Severity stratification in hypercalcemia begins with the corrected calcium level but must be adjusted for the rate of rise, underlying etiology (especially malignancy vs. PHPT), and symptom severity, a patient with a corrected Ca of 13.0 mg/dL from PTHrP-driven metastatic breast cancer and confusion is a medical emergency, whereas the same calcium level from long-standing PHPT with no symptoms can be managed electively.

The management of hypercalcemia is a time-critical intervention that follows a severity-stratified pathway. The goal is to lower serum calcium rapidly while identifying and treating the underlying cause. The approach is structured as a stepwise protocol, with escalation based on response and renal function.

Step 1: Initial Assessment and Severity Classification

Classify severity using corrected calcium (mg/dL): corrected Ca = measured Ca + 0.8 × (4 - albumin). Mild: 10.5-11.9 mg/dL; moderate: 12.0-13.9 mg/dL; severe: ≥14.0 mg/dL or any symptomatic hypercalcemia (altered mental status, coma, seizures, arrhythmias, hypotension). Severe cases require ICU admission; moderate cases can be managed on a medical ward; mild cases may be managed as outpatients if the cause is known and stable. Obtain immediate labs: ionized calcium, PTH, PTHrP, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, serum protein electrophoresis, and renal function. Do not delay treatment while awaiting results.

Step 2: First-Line Intervention - Volume Expansion and Calcitonin

Intravenous normal saline is the cornerstone of initial therapy. Administer a bolus of 200-500 mL/h for the first 1-2 hours, then continue at 100-200 mL/h to achieve a urine output of 100-150 mL/h. Caution is needed in patients with heart failure or severe renal impairment; consider central venous pressure monitoring. Volume expansion corrects dehydration, enhances urinary calcium excretion, and lowers calcium by 1-2 mg/dL within 24-48 hours.

Calcitonin provides a rapid but transient reduction. Give 4-8 IU/kg intramuscularly or subcutaneously every 6-12 hours. Onset of action is within 2-4 hours, but tachyphylaxis develops after 48 hours due to receptor downregulation ^[115]C4 (4). Calcitonin is useful as a bridge while bisphosphonates take effect.

Step 3: Bisphosphonates - Definitive First-Line Antiresorptive Therapy

Pamidronate 60-90 mg intravenously over 2-4 hours or zoledronic acid 4 mg intravenously over 15 minutes are the preferred bisphosphonates. They inhibit osteoclast-mediated bone resorption, lowering calcium by 1-2 mg/dL within 2-4 days, with a nadir at 4-7 days. In a randomized trial of alendronate (70 mg weekly) in acute spinal cord injury, bisphosphonate therapy prevented hypercalcemia and preserved bone mineral density ^[94]A1b (1b). Zoledronic acid is more potent than pamidronate and is the standard for malignancy-associated hypercalcemia; a comparative trial in osteogenesis imperfecta showed zoledronic acid effectively suppressed bone turnover ^[106]A1b (1b). Avoid zoledronic acid if creatinine clearance is <35 mL/min; pamidronate may be used with caution but is also nephrotoxic. Monitor serum calcium, creatinine, and electrolytes.

Step 4: Second-Line and Refractory Hypercalcemia

Denosumab is a RANKL inhibitor that provides sustained antiresorptive effect without renal clearance. Administer 120 mg subcutaneously; it can be repeated every 4 weeks. Denosumab is particularly valuable in patients with chronic kidney disease (CKD) where bisphosphonates are contraindicated. A case report documented successful use of denosumab for immobilization hypercalcemia in a patient with CKD stage 4, with calcium normalizing within 7 days ^[109]C4 (4). In a randomized trial in children with osteogenesis imperfecta, denosumab every 6 months increased bone density and was well tolerated ^[106]A1b (1b).

Glucocorticoids are indicated for hypercalcemia driven by elevated 1,25-dihydroxyvitamin D, such as in granulomatous diseases (sarcoidosis, tuberculosis) or vitamin D intoxication. Give hydrocortisone 100-200 mg intravenously every 6 hours or prednisone 40-60 mg orally daily. Glucocorticoids reduce extrarenal 1α-hydroxylase activity and intestinal calcium absorption. In a case of disseminated granulomatous myositis, prednisone rapidly corrected hypercalcemia ^[80]C4 (4). Glucocorticoids are also effective in adrenal insufficiency presenting with hypercalcemia ^[115]C4 (4).

Dialysis with a low-calcium dialysate (1.0-1.25 mmol/L) is reserved for severe, refractory hypercalcemia, especially when accompanied by acute kidney injury or volume overload. It rapidly removes calcium and is life-saving. Cases of hypercalcemia in hypophosphatasia and tumoral calcinosis have been managed with hemodialysis ^{[108]C4[112]C4} (4).

Step 5: Monitoring and Titration

Monitor corrected calcium every 6-12 hours initially, then daily once stable. Also monitor serum creatinine, magnesium, potassium, and phosphate. Adjust IV fluid rate based on urine output and volume status. If calcium does not decrease by ≥1 mg/dL after 48 hours of fluids and bisphosphonate, add calcitonin (if not already given), consider denosumab, and re-evaluate the etiology. If calcium continues to rise, initiate dialysis.

Step 6: Resolution and Transition to Chronic Management

Once corrected calcium falls below 12 mg/dL and symptoms resolve, transition to oral bisphosphonates (e.g., alendronate 70 mg weekly) or continue denosumab 120 mg SC every 4 weeks for maintenance. Address the underlying cause definitively: parathyroidectomy for primary hyperparathyroidism , chemotherapy or radiotherapy for malignancy, withdrawal of offending drugs (lithium, thiazides, vitamin D), or treatment of granulomatous disease.

Drug / Modality Comparison Table

Dosing Table

Treatment Failure Protocol

If corrected calcium has not decreased by ≥1 mg/dL after 48 hours of fluids plus bisphosphonate: (1) add calcitonin if not already used; (2) consider denosumab 120 mg SC; (3) check for volume overload and adjust fluids; (4) re-evaluate the underlying cause (e.g., missed malignancy, granulomatous disease, vitamin D intoxication). If calcium continues to rise or symptoms worsen, proceed to dialysis.

What NOT to Do

• Do NOT administer phosphate supplements - they can precipitate calcium phosphate crystals in renal tubules, causing acute phosphate nephropathy and worsening renal function ^[114]C4 (4).
• Do NOT use loop diuretics (e.g., furosemide ) unless the patient is volume overloaded; they can exacerbate dehydration and are not recommended as first-line therapy.
• Do NOT use bisphosphonates in acute renal failure without careful consideration. Zoledronic acid is contraindicated if CrCl <35 mL/min; pamidronate carries a risk of nephrotoxicity. Denosumab is preferred in this setting ^[109]C4 (4).
• Do NOT rely on calcitonin as monotherapy for sustained control - tachyphylaxis limits its use to the first 48 hours.

Controversies and Guideline Disagreement

No major guideline disagreements identified for this topic in the reviewed evidence. The choice between bisphosphonates and denosumab in patients with normal renal function is guided by cost, availability, and patient preference; both are effective. In CKD, denosumab is favored due to safety profile ^[109]C4 (4).

Pearl: In severe hypercalcemia (corrected Ca ≥14 mg/dL or symptomatic), initiate aggressive IV fluids and calcitonin for rapid reduction while awaiting bisphosphonate effect; use denosumab as first-line in patients with renal impairment (CrCl <30 mL/min) where bisphosphonates are contraindicated ^{[109]C4[115]C4}.

The preceding sections have guided the clinician through acute stabilization and the immediate decision to admit or discharge. Once the patient is hemodynamically stable and the acute calcium elevation is under control, the focus shifts to the long-term strategy: selecting the definitive or chronic treatment modality, replacement, suppression, or surgical cure, and then titrating therapy to a defined biochemical target. The choice hinges entirely on the underlying etiology, which has been established through the paired-hormone workup described in Diagnosis and Workup.

Step 1: Classify the Axis, Decide Whether to Replace, Suppress, or Excise

The three therapeutic paradigms map directly onto the PTH-vitamin D axis:

• Definitive surgical cure is the goal for sporadic primary hyperparathyroidism (PHPT) and parathyroid carcinoma . The Endocrine Society Clinical Practice Guideline and the European expert consensus (ESE 2022) both recommend parathyroidectomy as the only definitive therapy for symptomatic PHPT or for asymptomatic patients meeting guideline criteria ^{[38]A1c [3]A1c}. For parathyroid carcinoma, en bloc resection of the tumor with ipsilateral thyroid lobectomy is required, as incomplete resection carries a high recurrence rate ^[84]D5.

• Suppression therapy is indicated when the hypercalcemia is driven by a parathyroid-independent or non-surgical axis: hypercalcemia of malignancy (HCM) from PTHrP or local osteolysis, granulomatous disease (calciferol-driven), or vitamin D intoxication. Here, the goal is to block the effector mechanism with bisphosphonates, denosumab, or glucocorticoids.

• Replacement therapy is reserved for the rare patient who has undergone definitive treatment (e.g., parathyroidectomy) and develops transient or permanent hypoparathyroidism . The ATA 2018 statement recommends calcium and active vitamin D (calcitriol) replacement, titrated to maintain serum calcium in the low-normal range and avoid hypercalciuria ^[40]A1c.

Correct classification is the single most important decision. Operating on a patient with familial hypocalciuric hypercalcemia (FHH) is harmful and unnecessary ^[74]C4; failing to operate on a patient with parathyroid carcinoma delays curative resection. The CCCR and genetic testing (CASR, AP2S1, GNA11) distinguish FHH from PHPT before any irreversible intervention ^[25]D5.

Step 2: Definitive Therapy for Primary Hyperparathyroidism, Parathyroidectomy

Parathyroidectomy is the only curative intervention for sporadic PHPT. The Endocrine Society guideline states that surgery is indicated for all patients with symptomatic disease and for asymptomatic patients meeting any one of the following criteria: serum calcium >1.0 mg/dL above the upper limit of normal, creatinine clearance <60 mL/min, 24-hour urinary calcium >400 mg (though this cutoff is debated), bone mineral density T-score ≤-2.5 at any site, or age <50 years ^{[38]A1c [68]D5}.

The ESE 2022 European expert consensus recommends bilateral neck exploration with intraoperative PTH monitoring as the gold standard, achieving a cure rate exceeding 95% in experienced hands ^[3]A1c. A systematic review and meta-analysis of 9 studies including 14,257 patients reported a long-term recurrence rate of only 2.6% (95% CI 1.4-4.2%) at 5 years, rising to 6.9% (95% CI 5.2-8.9%) at 10 years after successful parathyroidectomy ^[78]A1a (1a). The median time to recurrence was 7.4 years, and the retreatment rate was 0.5%. Most recurrences are due to missed multiglandular disease.

Dosing and Monitoring Table, Surgical and Pharmacologic [[Management]] of PHPT

Cinacalcet, a calcimimetic, is reserved for patients who are not surgical candidates or who refuse surgery. In a Phase 3 double-blind RCT, 84% of cinacalcet-treated patients achieved a normal serum calcium by week 28 compared to 6% of placebo (p < 0.001) ^[118]A1b (1b). The effect is durable: PTH fell by a mean of 7.6 pmol/L. Cinacalcet is also FDA-approved for parathyroid carcinoma and for severe secondary hyperparathyroidism in dialysis.

Step 3: Suppression Therapy for Non-PTH-Driven Hypercalcemia, Bisphosphonates, Denosumab, and Glucocorticoids

When the PTH is suppressed, the driver is either PTHrP (humoral HCM), local osteolysis ( multiple myeloma , breast cancer bone metastases), or calciferol excess (granulomatous disease, vitamin D intoxication).

Antiresorptive Agents, First-Line for HCM

Zoledronic acid 4 mg IV over 15 minutes is the preferred bisphosphonate for acute HCM and for long-term suppression to prevent recurrence. A single dose achieves normocalcemia in 60-70% of patients within 4-7 days, with a median duration of response of 30 days ^[38]A1c (1c). For patients with renal impairment (CrCl <35 mL/min), the Endocrine Society guideline recommends either dose reduction or substitution with denosumab ^[38]A1c.

Denosumab 120 mg SC weekly for 4 doses, then every 4 weeks, a RANKL inhibitor, is the agent of choice for bisphosphonate-refractory HCM. In a single-arm study of patients with persistent HCM (corrected serum calcium >12.5 mg/dL) despite bisphosphonate therapy, 80% achieved a response (CSC <11.5 mg/dL) within 10 days, and the median duration of response was 104 days ^[119]B2b (2b). The Endocrine Society 2023 guideline gives a conditional recommendation for denosumab after bisphosphonate failure (low-quality evidence) ^[38]A1c.

For multiple myeloma, a Cochrane network meta-analysis demonstrated that zoledronic acid and pamidronate both reduce skeletal-related events (SREs) compared to placebo: ZA reduces SREs by 32% (RR 0.68, 95% CI 0.56-0.80) ^[55]A1a (1a). NNT = 6 to prevent one SRE. Denosumab was non-inferior to zoledronic acid for SRE prevention in myeloma in the pivotal trial.

Glucocorticoids for Calciferol-Mediated Hypercalcemia

For hypercalcemia driven by granulomatous disease (sarcoidosis, tuberculosis, Blau syndrome) or lymphoma (1,25-dihydroxyvitamin D excess), glucocorticoids are the mainstay. Prednisone 0.5-1 mg/kg/day (or equivalent) for 10-14 days, then taper to the lowest effective dose, blocks the extrarenal 1α-hydroxylase. In sarcoidosis, 90% of patients respond within 1 week ^[29]D5 (5). For vitamin D intoxication, the same approach is effective, though the half-life of 25(OH)D is weeks; a brief course of glucocorticoids accelerates resolution.

Dosing Table, Antiresorptive and Suppressive Agents

Step 4: Definitive Therapy for Parathyroid Carcinoma, En Bloc Resection

Parathyroid carcinoma (PC) accounts for <1% of PHPT but carries a mortality of 30-50% at 10 years. The Endocrine Society 2023 guideline on PC strongly recommends en bloc resection of the tumor with the ipsilateral thyroid lobe and any adherent structures at the initial operation ^[84]D5 (5). As described in a recent case report, incomplete resection leads to relentless recurrence, with a Ki-67 index >5% suggesting aggressive behavior ^[73]C4. For inoperable or metastatic PC, cinacalcet controls hypercalcemia, and denosumab or bisphosphonates manage bone disease. Palliative re-resection of local recurrence may improve symptom control.

Step 5: Monitoring and Titration, The Treat-to-Target Framework

Long-term management requires a defined biochemical target and a fixed surveillance schedule.

• After parathyroidectomy for PHPT: Measure serum calcium and PTH at 2 weeks to confirm cure, then at 6 months and annually for at least 10 years to detect the 6.9% late recurrence ^[78]A1a. Measure bone density at 2 years post-surgery, then per osteoporosis guidelines.

• On cinacalcet: Titrate to maintain serum calcium within the normal range (8.5-10.2 mg/dL, or ionized Ca 1.15-1.30 mmol/L). Check calcium 1 week after each dose increment. Monitor PTH quarterly ^[118]A1b.

• On chronic bisphosphonate or denosumab for HCM: Re-check corrected serum calcium every 2-4 weeks during the first 3 months, then every 3 months. The Endocrine Society guideline recommends re-treatment when corrected calcium rises above 11.0 mg/dL ^[38]A1c.

• On glucocorticoids for granulomatous disease: Taper to the lowest dose that maintains normocalcemia, then monitor calcium monthly. The hypercalcemia of sarcoidosis is often seasonal (more UV exposure in summer); anticipate seasonal increases ^[29]D5.

Step 6: What NOT to Do, Ineffective and Harmful Long-Term Strategies

• Do NOT recommend a low-calcium diet for PHPT. In PHPT, intestinal calcium absorption is already enhanced by PTH-driven 1,25(OH)2D; restricting calcium may worsen PTH elevation and bone loss. The Endocrine Society guideline recommends normal calcium intake (1000-1200 mg/day) ^[68]D5. The only exception is calciferol-mediated hypercalcemia, where dietary calcium restriction reduces the filtered load.

• Do NOT use thiazide diuretics to treat hypercalcemia. Thiazides decrease renal calcium excretion and may worsen hypercalcemia. They are used for hypocalciuric states, not hypercalcemia.

• Do NOT administer vitamin D supplementation (including calcitriol) to patients with active HCM or granulomatous hypercalcemia. Exogenous vitamin D will worsen the hypercalcemia ^[29]D5. Once the HCM is resolved, bone health may require vitamin D, but only after normocalcemia is sustained for 3 months.

Controversies and Guideline Disagreement

Pearl: For the patient with confirmed sporadic primary hyperparathyroidism who meets any Endocrine Society surgical criterion, parathyroidectomy offers a >95% cure rate at 10 years ^[78]A1a; for those with hypercalcemia of malignancy, zoledronic acid 4 mg IV achieves rapid calcium lowering, and denosumab 120 mg SC is the rescue agent for bisphosphonate-refractory cases ^[119]B2b.

Inherited Syndromes Associated with Hypercalcemia

Hypercalcemia is frequently the earliest or sole biochemical clue to an underlying inherited tumor syndrome. Multiple endocrine neoplasia type 1 (MEN1) is the most common genetic cause of primary hyperparathyroidism (PHPT), with hypercalcemia developing in nearly all mutation carriers by age 50 ^[85]D5. PHPT is the first manifestation in >90% of MEN1 patients, often presenting in the third decade ^[85]D5. The MEN1 gene encodes menin, a tumor suppressor; loss-of-function mutations lead to parathyroid, pancreatic neuroendocrine, and pituitary tumors. Gender influences phenotype: pancreatic gastrinomas are more prevalent in males, while pituitary tumors are more frequent in females ^[43]B2b. All MEN1 patients with hypercalcemia should undergo surgery, with subtotal parathyroidectomy (removal of 3-3.5 glands) recommended to balance cure with preservation of parathyroid function ^[85]D5.

Multiple endocrine neoplasia type 2A (MEN2A) results from RET proto-oncogene mutations (most commonly p.C634R) and includes medullary thyroid carcinoma, pheochromocytoma, and PHPT. PHPT occurs in 10-30% of MEN2A patients and can be the presenting feature, even in young children ^[82]C4. Hypercalcemia in MEN2A is typically mild but warrants parathyroidectomy at the time of thyroidectomy for medullary carcinoma.

Multiple endocrine neoplasia type 4 (MEN4) is a rare autosomal dominant syndrome caused by CDKN1B mutations encoding p27/Kip1. The phenotype overlaps with MEN1: PHPT, pituitary tumors, and occasionally Cushing disease ^[63]C4. MEN4 should be considered in familial hypercalcemia with negative MEN1 testing.

Familial hypocalciuric hypercalcemia type 1 (FHH1) is a benign autosomal dominant condition due to inactivating mutations in the calcium-sensing receptor (CASR) gene ^{[13]B2a[129]C4}. Affected individuals have lifelong mild hypercalcemia, low urinary calcium excretion (fractional excretion of calcium <1%), and inappropriately normal or mildly elevated PTH. FHH1 must be distinguished from PHPT to avoid unnecessary parathyroidectomy ^[90]B3b. Key discriminators include younger age at diagnosis, lower serum calcium, higher serum magnesium, and family history ^[90]B3b. The CASRdb database catalogs disease-associated CASR variants to aid diagnosis ^[13]B2a.

Hyperparathyroidism-jaw tumor syndrome (HPT-JT) is caused by germline CDC73 mutations and predisposes to parathyroid carcinoma (PC). PC accounts for <1% of PHPT but should be suspected in severe hypercalcemia (>14 mg/dL) with end-organ complications ^[84]D5. Somatic CDC73 mutations are found in up to 80% of sporadic PC; germline mutations occur in ~30% ^[84]D5. En bloc resection with ipsilateral thyroid lobectomy is the standard of care ^[84]D5.

Other rare syndromes include:

• Williams-Beuren syndrome: microdeletion on 7q11.23, associated with infantile hypercalcemia (often calcitriol-mediated), nephrocalcinosis, and characteristic facies ^[75]C4.
• Blau syndrome: NOD2 mutation causing granulomatous inflammation and calcitriol-mediated hypercalcemia, treated with corticosteroids ^[91]C4.
• Mahvash syndrome: biallelic GCGR mutations leading to glucagon cell hyperplasia and PTH-independent hypercalcemia ^[128]C4.
• NaPi-IIa deficiency (SLC34A1 mutations): causes idiopathic infantile hypercalcemia with proximal tubulopathy and nephrocalcinosis ^[127]C4.
• McCune-Albright syndrome: GNAS mosaicism causing fibrous dysplasia, café-au-lait spots, and endocrine hyperfunction; hypercalcemia can occur after denosumab withdrawal ^{[126]B2b[132]A1a}.

Genetic Testing and Counseling

Genetic testing is indicated for any patient with hypercalcemia and one or more of: family history of hypercalcemia or endocrine tumors, young age (<40 years), multiglandular parathyroid disease, or syndromic features. First-line testing includes MEN1, RET, CASR, and CDC73 sequencing ^{[13]B2a[85]D5}. For FHH1, CASR testing confirms the diagnosis and prevents unnecessary surgery ^[129]C4. In MEN1, genetic counseling and cascade screening of at-risk relatives are essential ^[85]D5.

Co-Axis Effects and Cross-System Surveillance

Hypercalcemia itself perturbs other endocrine axes. Calcium-sensing receptor (CASR) is expressed in pancreatic β-cells; in patients with concurrent FHH and insulinoma , calcium infusion during arterial stimulation venous sampling (ASVS) stimulates insulin secretion via CASR, aiding tumor localization ^[83]C4. PTHrP mediates hypercalcemia in pregnancy and malignancy; severe PTHrP-driven hypercalcemia (up to 21 mg/dL) can occur in the third trimester and resolves after delivery ^[130]C4. Ectopic hormone syndromes such as ACTH and PTHrP co-secretion from hepatoblastoma can cause concurrent Cushing's syndrome and hypercalcemia ^[67]C4. Cardiovascular effects of chronic hypercalcemia include hypertension , arrhythmias, endothelial dysfunction, and impaired glucose metabolism, warranting periodic cardiovascular assessment in PHPT ^[50]D5. Tumor-induced osteomalacia (TIO) due to FGF23-secreting tumors can be masked by coexisting hypercalcemic hyperparathyroidism; persistent hypophosphatemia after parathyroidectomy should prompt evaluation for TIO ^[31]C4.

Pearl: Hypercalcemia is often the sentinel clue to MEN1, MEN2A, FHH, or HPT-JT; genetic testing and family screening are mandatory in young patients or those with multiglandular disease, and cross-axis surveillance for cardiovascular, pancreatic, and pituitary involvement should be integrated into long-term follow-up ^{[43]B2b[85]D5}.

Chronic hypercalcemia, regardless of etiology, inflicts progressive damage across multiple organ systems. The severity and tempo of complications depend on the degree and duration of calcium elevation, the underlying cause, and the patient's baseline vulnerability. This section provides a compartmentalized playbook for ICU and ward-based surveillance, prevention, and management of the major complications.

Bone and Musculoskeletal Complications

Bone disease is the most common long-term complication of primary hyperparathyroidism (PHPT), driven by PTH-mediated osteoclast activation. Overt skeletal involvement, osteitis fibrosa cystica, brown tumors, pathological fractures, now occurs in fewer than 5% of patients in resource-rich settings but remains prevalent in populations with delayed diagnosis ^[68]D5[84]D5. In a young man with parathyroid carcinoma , a pathological radius fracture was the presenting event ^[72]C4. Even in mild PHPT, bone mineral density (BMD) is reduced at cortical sites (distal radius), while trabecular bone is relatively preserved; however, vertebral fracture risk is increased independent of BMD ^[68]D5.

Surveillance: Dual-energy X-ray absorptiometry (DXA) at the lumbar spine, total hip, femoral neck, and distal one-third radius is recommended at diagnosis and every 1-2 years thereafter in patients not undergoing parathyroidectomy ^[68]D5. Management: After parathyroidectomy, BMD increases by 10-14% at the hip over 5 years ^[68]D5. When surgery is not pursued, antiresorptive therapy with bisphosphonates (e.g., alendronate 70 mg weekly) reduces vertebral fracture risk, though data in PHPT are limited. For patients with severe hypercalcemia due to malignancy, intravenous zoledronic acid 4 mg reduces skeletal-related events by 23% (HR 0.77, 95% CI 0.65-0.90) ^[123]A1a. NNT = 14 to prevent one skeletal-related event ^[123]A1a.

Renal Complications

Nephrolithiasis and nephrocalcinosis are classic sequelae of chronic hypercalcemia. In PHPT, 15-20% of patients have a history of kidney stones; the risk correlates with urinary calcium excretion >10 mmol/day (400 mg/day) ^[68]D5. Cortical bone loss at the distal radius, reflecting prolonged PTH excess, is a surrogate for stone risk. Chronic kidney disease (CKD) develops in a subset, and in mild PHPT randomized to observation vs. surgery, no significant difference in eGFR decline was observed over 10 years ^[11]A1b. However, in parathyroid carcinoma or severe HCM, nephrocalcinosis can progress to end-stage renal disease requiring dialysis ^[14]C4.

Prevention and surveillance: Annual measurement of serum creatinine, eGFR, and 24-hour urinary calcium (if nephrolithiasis is present or suspected) is recommended. Maintenance of adequate hydration (≥2 L/day) reduces stone risk. Medical management: Calcium-sensing receptor agonists (cinacalcet 30-60 mg twice daily) lower both serum calcium and urinary calcium excretion, and may reduce stone recurrence ^[3]A1c. In the setting of nephrocalcinosis with CKD, dose adjustment of bisphosphonates and cinacalcet is mandatory.

Cardiovascular Complications

Both calcium and PTH exert direct effects on the cardiovascular system. PTH receptors are present on cardiomyocytes and vascular smooth muscle, and hypercalcemia shortens the QT interval and predisposes to ventricular arrhythmias , particularly torsades de pointes ^[47]D5[50]D5. Hypertension is present in 30-50% of PHPT patients at diagnosis, and while parathyroidectomy may lower mean systolic BP by 5-7 mmHg, normalization is not guaranteed ^{[47]D5[11]A1b}.

Arrhythmia surveillance: A 12-lead ECG is required at presentation; a QTc <360 ms in the context of hypercalcemia warrants continuous telemetry. Valvular calcification (mitral and aortic) is more prevalent in PHPT but does not clearly regress after surgery ^[47]D5. Heart failure can be precipitated by calcium-mediated myocardial stunning. Management includes aggressive hydration, heart-rate control (beta-blockers favored), and tight electrolyte repletion (magnesium, potassium) to suppress ectopy.

Autonomic and Gastrointestinal Complications

Hypercalcemia inhibits smooth muscle contractility, producing ileus, constipation, and nausea. In severe hypercalcemia (corrected calcium >3.5 mmol/L [14 mg/dL]), paralytic ileus is common and may mimic acute abdomen. Urinary retention and orthostatic hypotension result from autonomic dysfunction.

Management: Bowel regimen with osmotic laxatives (polyethylene glycol 17 g daily) and prokinetic agents (metoclopramide 10 mg three times daily) is initiated early. For urinary retention, indwelling catheterization is temporary but may precipitate infection. Correction of calcium toward normal rapidly reverses ileus.

Thromboembolic Complications

Hypercalcemia is a prothrombotic state; calcium activates clotting factors and increases platelet aggregation. Venous thromboembolism (VTE), DVT and PE, complicates hypercalcemic malignancy in particular. In a cohort of HCM patients, the in-hospital VTE rate was 4.8% ^[38]A1c. Prophylaxis: Subcutaneous unfractionated heparin 5000 U three times daily or low-molecular-weight heparin ( enoxaparin 40 mg daily) is recommended for all hospitalized hypercalcemic patients without contraindications ^[38]A1c.

Hospital-Acquired Complications

Immobilized, acutely ill hypercalcemic patients are at risk for the full suite of ICU complications.

Respiratory Monitoring and Intubation Criteria

Altered mental status from severe hypercalcemia compromises airway protection. The decision to intubate integrates calcium level, Glasgow Coma Scale ( GCS ), and work of breathing.

Pearl: Forced vital capacity (FVC) is a practical bedside tool; an FVC <15 mL/kg predicts impending respiratory failure and should prompt early elective intubation before emergency, the 'crash' airway has a 10-fold higher complication rate.

Pain Management

Pain in hypercalcemic patients has three sources: bone pain from metastases or fractures, renal colic from stones, and abdominal pain from ileus.

• Bone pain: NSAIDs (ibuprofen 800 mg three times daily) block prostaglandin-mediated osteolysis and provide short-term relief; avoid in CKD. Opioids ( morphine 5-10 mg q4h PRN or hydromorphone 1-2 mg q4h) are first-line for severe pain, but they worsen ileus and sedation, use bowel regimen concurrently. Calcitonin (4-8 IU/kg subcutaneous q12h) provides acute analgesic effect within 24-48 hours but tachyphylaxis develops ^[124]A1a.
• Renal colic: IV ketorolac 30 mg followed by oral ibuprofen, plus aggressive hydration.
• Abdominal pain: Treat ileus with bowel rest, nasogastric decompression if vomiting, and prokinetics.

Rehabilitation

Deconditioning is profound after prolonged hypercalcemic hospitalization. When to start: As soon as corrected calcium falls below 3.0 mmol/L (12 mg/dL) and the patient is hemodynamically stable. Modalities: Passive range-of-motion for the ICU patient; progressive resistance training for the ward patient. In post-parathyroidectomy PHPT, physical function improves by 12 weeks, though muscle strength gains plateau at 6 months ^[68]D5.

Pearl: Chronic hypercalcemia is a multi-system disease that demands structured surveillance of bone, kidney, and heart, plus aggressive prevention of secondary hospital-acquired complications. Early mobilization, VTE prophylaxis, and a strict bowel and bladder protocol are as important as any intravenous therapy.

The trajectory of hypercalcemia depends entirely on its etiology, severity, and the rapidity of intervention. For patients with mild primary hyperparathyroidism (PHPT), the natural history is often indolent; a 10-year prospective study found that most patients with serum calcium <1 mg/dL above the upper limit of normal and without target organ involvement did not progress to surgical criteria or develop complications ^[68]D5. However, even in mild PHPT, untreated disease carries an increased risk of vertebral fractures (odds ratio 2.5) and nephrolithiasis (lifetime incidence 15-20%), and cardiovascular mortality is elevated, though the absolute risk remains low ^{[88]D5[134]D5}. Parathyroidectomy reverses some of this excess risk; after successful surgery, bone mineral density improves by 8-12% at the lumbar spine over 3 years, and the risk of renal colic declines to that of the general population ^[88]D5.

In contrast, hypercalcemia of malignancy (HCM) portends a grim prognosis. Median survival after the diagnosis of HCM ranges from 30 days (for solid tumors with extensive bone metastases) to 12 months (for multiple myeloma with limited bone disease) ^{[99]C4[97]B3b}. The presence of PTHrP-mediated hypercalcemia in breast cancer is associated with a 2.5-fold increase in the hazard of death (HR 2.54, 95% CI 1.72-3.76), independent of tumor stage, according to a recent meta-analysis ^[28]A1a. Serum calcium >14 mg/dL (3.5 mmol/L) at presentation carries a mortality rate of approximately 50% at 30 days, even with aggressive therapy ^[99]C4. The cause of death is usually the underlying malignancy rather than hypercalcemia per se, but severe hypercalcemia can precipitate lethal arrhythmias, coma, and renal failure ^[97]B3b.

Natural History by Etiology

The trajectory of untreated hypercalcemia varies markedly:

• Primary hyperparathyroidism (PHPT): In the 10% of patients who present with symptomatic hypercalcemia (calcium >12 mg/dL), the disease progresses steadily over years, with nephrocalcinosis and bone loss (cortical > trabecular) being the dominant morbidities ^[68]D5[88]D5. In asymptomatic mild PHPT, only about 25% will develop a surgical indication over 10 years ^[68]D5. Normocalcemic hyperparathyroidism (NPHPT) progresses to hypercalcemic PHPT at a rate of approximately 2% per year ^[137]B2b.
• Malignancy-associated HCM: HCM is typically a late-stage complication, with 80% of cases occurring within 6 months of death ^[99]C4. The exception is multiple myeloma, where HCM can be the presenting feature and may respond durably to therapy ^{[55]A1a[56]A1a}.
• Familial hypocalciuric hypercalcemia (FHH): FHH type 1 (due to CASR mutation) is benign throughout life; affected individuals have a normal life expectancy and do not require intervention ^[90]B3b.
• CYP24A1 deficiency (idiopathic infantile hypercalcemia): In infants, severe hypercalcemia (up to 4.73 mmol/L) can lead to nephrocalcinosis, failure to thrive, and seizures if unrecognized; with prompt diagnosis and dietary vitamin D restriction, calcium normalizes and neurodevelopment is typically normal ^{[75]C4[51]C4[62]C4}.
• Vitamin D intoxication: The calcium elevation resolves over weeks to months after discontinuation of vitamin D, but nephrocalcinosis and renal impairment may persist ^{[53]C4[42]A1b}.

Special Populations

Pregnancy and Lactation

Pregnancy is a unique state in which calcium homeostasis is dramatically altered. Maternal calcitriol levels increase 2-3-fold, intestinal calcium absorption doubles, and PTHrP produced by the placenta and breasts can exceed normal levels by 3-fold ^[138]A1a. These changes can unmask or exacerbate hypercalcemia:

• PHPT in pregnancy: Occurs in approximately 1 in 3000 to 1 in 10,000 pregnancies. Fetal complications include intrauterine growth restriction, preterm labor , and neonatal hypocalcemia (due to suppression of the fetal parathyroid axis) ^{[3]A1c[138]A1a}. Maternal complications include nephrolithiasis, pancreatitis, and preeclampsia. Severe hypercalcemia (calcium >14 mg/dL) in the third trimester is a medical emergency; delivery (by C-section if <34 weeks) reduces PTHrP from the placenta and quickly lowers calcium ^{[130]C4[136]C4}. Medical therapy with IV fluids, calcitonin (a Category B drug in pregnancy), and bisphosphonates can be used but with caution, pamidronate 60-90 mg IV has been administered in refractory cases, though its use is limited by potential fetal skeletal effects ^[3]A1c.
• Lactating women with PHPT: Breastfeeding can paradoxically lower maternal calcium due to increased calcium loss in milk and high calcitriol levels; however, lactation can also trigger PTHrP-mediated hypercalcemia, particularly in women with underlying PHPT ^{[138]A1a[3]A1c}. Bisphosphonates are minimally excreted in breast milk and are considered compatible with breastfeeding ^[3]A1c.
• Hypoparathyroidism in pregnancy: Requires close monitoring; doses of calcium and calcitriol often need to be increased, particularly in the third trimester, and decreased postpartum ^[138]A1a. The goal is to maintain albumin-corrected calcium in the low-normal range (8.0-8.5 mg/dL) to protect the fetus from hypercalcemia ^[138]A1a.

Pediatric Patients

Hypercalcemia in children is rare but serious. The most frequent causes in infancy are Williams-Beuren syndrome (prevalence 1 in 7500) and idiopathic infantile hypercalcemia (CYP24A1 deficiency) ^[75]C4[51]C4. Treatment for CYP24A1 deficiency includes dietary vitamin D restriction and a low-calcium formula; severe cases may require bisphosphonates. Denosumab is increasingly used off-label for pediatric osteogenesis imperfecta , but it carries a unique risk of rebound hypercalcemia, serum calcium can rise to 12-14 mg/dL after discontinuation, with metaphyseal sclerotic band fractures observed in children on treatment (OR 3.2, 95% CI 1.8-5.6) ^{[24]B3b[106]A1b}. The ATA guideline recommends that children receiving denosumab have serum calcium monitored monthly for 6 months after the last dose ^[40]A1c.

Elderly Patients

Older adults are more susceptible to hypercalcemia due to age-related decline in renal function, reduced thirst response, and higher prevalence of polypharmacy (e.g., thiazides, vitamin D supplements, lithium). Mild PHPT in elderly patients (age >75) is often managed conservatively; parathyroidectomy is rarely indicated unless calcium >11.5 mg/dL or there is evidence of target organ damage ^[88]D5[68]D5. Bisphosphonate therapy is safe, but renal function must be monitored closely, zoledronic acid infusion should be delayed if eGFR <35 mL/min/1.73m² ^{[5]A1a[55]A1a}. Calcitonin is effective for rapid calcium lowering but has a short half-life; its use in the elderly is limited by tachyphylaxis and a 20% rate of nausea ^[124]A1a. Denosumab may be preferred in elderly patients with renal impairment because it is not renally cleared, but it carries a risk of severe (grade 3 or 4) hypocalcemia (approximately 5-10% in patients with advanced cancer) ^{[119]B2b[120]D5}.

Prevention and Screening

Prevention strategies target the underlying cause:

• PHPT: No known primary prevention. Screening with serum calcium is recommended in postmenopausal women and in patients with nephrolithiasis or osteoporosis by the ATA ^[40]A1c. Once diagnosed, treatment of asymptomatic PHPT to prevent complications is guided by the Endocrine Society guidelines ^[68]D5.
• Malignancy-associated HCM: Prevention is achieved through management of the underlying cancer. In multiple myeloma, prophylactic bisphosphonates (zoledronic acid 4 mg IV monthly or pamidronate 90 mg IV monthly) reduce the incidence of hypercalcemia by 30-50% (NNT = 10 to prevent one episode) ^{[55]A1a[56]A1a[123]A1a}. In breast cancer with bone metastases, bisphosphonates or denosumab reduce skeletal-related events (fracture, radiation to bone, spinal cord compression) by 15-20% ^[5]A1a.
• Vitamin D intoxication: Avoid supplement doses >4000 IU/day in adults (the upper tolerable intake level). Population-based randomized trials, including the VITAL study of 2000 IU/day, found no increased risk of hypercalcemia (incidence <0.1%) ^[42]A1b. However, patients with CYP24A1 mutations or sarcoidosis are more susceptible and should undergo periodic calcium monitoring ^{[62]C4[117]A1b}.
• Rebound hypercalcemia after denosumab: Prevention involves transitioning to a bisphosphonate (e.g., zoledronic acid 5 mg IV once) 6-8 weeks after the last denosumab dose in patients at high risk (children, those with renal failure) ^{[24]B3b[119]B2b}.

Pearl: The prognosis of hypercalcemia is determined primarily by its etiology and the promptness of treatment: mild PHPT has a 10-year survival >95% with conservative management, whereas malignancy-associated hypercalcemia carries a 30-day mortality of approximately 50% if serum calcium >14 mg/dL ^[68]D5[99]C4. Prevention through prophylactic bisphosphonates in high-risk populations (multiple myeloma, bone-metastatic cancer) reduces hypercalcemia incidence by a third ^[55]A1a.